Compounded Semaglutide vs Brand Cost Calculator

Brand Wegovy and Ozempic run 1,000 to 1,400 dollars per month cash, less with savings cards or insurance. Compounded semaglutide runs 150 to 400 per month. With FDA restrictions on compounding in flux, the cost difference is enormous, but durability of access matters.

$
$
$
$

Compounded Semaglutide vs Brand GLP-1: What is the Math?

Brand-name GLP-1 medications, Wegovy, Ozempic (semaglutide), Mounjaro, Zepbound (tirzepatide), run 1,000 to 1,400 dollars per month cash without insurance. Compounding pharmacies have offered semaglutide and tirzepatide for 150 to 400 dollars per month during FDA shortage status. The gap is enormous, and so is the regulatory uncertainty around continued compounding access.

Why Compounded Is So Much Cheaper

  • No R&D recovery: Compounding pharmacies use bulk API rather than amortizing billions in clinical trial costs.
  • No marketing: Direct-to-consumer telehealth eliminates the brand advertising spend.
  • No middlemen: Pharmacy-direct sales avoid wholesaler and pharmacy benefit manager markups.
  • Bulk API pricing: Semaglutide raw API costs roughly 50 to 100 dollars per gram; a monthly dose contains around 8 to 17 mg.

What the Calculator Shows

Total Compounded = Monthly Compounded × Months
Total Brand = (Cash − Savings Card Discount OR Copay) × Months

Regulatory Status in 2026

Compounding semaglutide and tirzepatide is permitted under FDA rules only when the brand drug is on FDA shortage list. Tirzepatide came off shortage in October 2024, restricting most compounding. Semaglutide came off shortage in February 2025. Some compounding pharmacies continue under personalized dosing exemptions but the legal landscape is in flux. Verify your compounding pharmacy is licensed (503A or 503B) and not operating in a gray zone.

How to Use This Calculator

  1. Compounded monthly, quoted price from a reputable telehealth provider or local compounding pharmacy.
  2. Brand cash price, current cash list price (Wegovy 1,350; Ozempic 1,000; Mounjaro 1,200; Zepbound 1,000-ish per month).
  3. Does insurance cover brand, 1 if your insurance covers (most plans do not for weight loss).
  4. Brand copay, what you actually pay if covered.
  5. Savings card discount, Novo and Lilly offer 500 to 700 dollar monthly savings cards for commercial-insured patients.
  6. Months on drug, typical course is 12 to 24 months for weight loss, longer for diabetes.

When Compounded Makes Sense

  • Brand is not covered by insurance.
  • You are willing to accept regulatory uncertainty about future access.
  • You have verified your compounder is reputable (USP-quality API, licensed pharmacy).
  • Cash savings of 700-plus dollars per month materially impact your finances.

When Brand Makes Sense

  • Your insurance covers it at 25 to 100 dollar copay.
  • Savings card brings effective price under 500 dollars per month.
  • You prioritize regulatory certainty and consistent supply chain.
  • Long-term clinical trial data on the exact branded formulation matters to you.

Frequently Asked Questions

Is compounded semaglutide safe?
Reputable 503A or 503B licensed compounding pharmacies using USP-grade API have safety profiles similar to brand. The risk is non-licensed operations or research-grade peptide sellers, these have been linked to contamination, mislabeling, and overdose incidents. Verify your provider is properly licensed and uses pharmaceutical-grade API. The FDA has issued multiple warnings about unregulated compounders.
Why is brand so expensive in the US?
Three reasons. First, US pharmaceutical pricing has no government price negotiation for most drugs. Second, the manufacturers (Novo Nordisk, Eli Lilly) face limited supply during peak demand, which keeps prices high. Third, pharmacy benefit managers and wholesalers add layered markups between manufacturer and patient. The same drug costs 5 to 10x more in the US than in Europe.
Will compounded GLP-1 still be available in 2027?
Uncertain. Both semaglutide and tirzepatide are off FDA shortage status as of 2025. Compounding pharmacies operating under personalized dosing exemptions face legal challenges. Lilly and Novo Nordisk are both actively pursuing FDA enforcement and state-level restrictions. Plan for the possibility that compounded access tightens or disappears.
What about savings cards?
Novo Nordisk offers a Wegovy savings card that can bring commercial-insured patients to 0 to 25 dollars per month for the first 6 months, then increases. Lilly offers similar for Zepbound. Read the fine print, savings cards require commercial insurance, exclude Medicare/Medicaid, and have monthly and lifetime caps. Often a great first-year option before evaluating long-term.

Practical Guide for Compounded Semaglutide vs Brand Cost Calculator

The regulatory environment for compounded GLP-1 is shifting rapidly. As of 2025, both semaglutide and tirzepatide have come off FDA shortage status, restricting most compounding. Telehealth companies that built businesses on compounded GLP-1 are pivoting to personalized dosing or brand prescribing. The 200-dollar-per-month compounded option may not persist long-term.

Best practice in 2026: explore brand savings cards first. Many commercial-insured patients can access Wegovy or Zepbound for 25 to 75 dollars per month through manufacturer savings programs, comparable to compounded pricing with full regulatory certainty.

If compounded is your path, verify the pharmacy is licensed (look up state board of pharmacy records), confirm they use USP-grade API, and avoid any provider selling research peptides or unlicensed "wellness" semaglutide. Price-too-good-to-be-true compounded products from unlicensed sellers carry real safety risks.

Review Checklist

  • Check Wegovy and Zepbound savings card eligibility first, often beats compounded.
  • Verify compounding pharmacy is licensed and uses USP-grade API.
  • Avoid research peptide or "wellness peptide" sellers, not the same product.
  • Plan for the possibility that compounded access tightens in 2026-2027.